Although consideration of risks associated with CT scans generally focuses on the effects of radiation and contrast agents, we have identified premedication as an additional risk among infants and children who undergo CT scans. As part of an intensive Pediatric Drug Surveillance (PeDS) Program, we evaluated adverse drug reactions (ADR) attributed t o medications given prior to CT scanning t o sedate 100 infants and children (ages 2 days to 16 yrs). ADR's attributed to premedication were observed in 12 patients (12%); 6 were of major severity, 4 were moderate and 2 were minor. Life-threatening cardiorespiratory depression/arrest occurred in 3 patients after meperidine, meperidine plus diazepam and morphine. Other reactions were CNS depression, behavior changes, voiding problems, respiratory compromise and vomiting. Premedications implicated were morphine, meperidine, promethazine, chlorpromazine, chloral hydrate and diazepam. The risk of an ADR was not materially affected by admission diagnosis or prior receipt of CNS depressants, but ADR risk was increased among older patients (5t yrs.), when > 3 premedication~ were used and when doses were higher than recommended. These observations suggest that ADR's to premedication~ must be considered when assessing the risk of CT scans in children, and that greater attention be paid t o developing appropriate CT scan premedication regimens.
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antagonist di hydroal prenolol , (-) [ HIDHA, t o rabbit placental menbranes was saturable t o a single class of s i t e s , KD=1.67+
.07(nM), n = l l and Bmax=326+33 fmles/mg. Agonist canpetition for the @AR was performed in the presence of the non-hydrolyzable GTP analog Gpp(NH)p (required f o r Hi1 1 coefficient = 1 ) and showed the potency order (-)is0 >> (-)epi > (-)norepi characteristic of the BZ subtype. However, canpetition experiments with subtype specif i c agents metoprolol (B1) and zinterol (B2) indicated that the rabbit placenta contained appraximtely equal populations of BAR subtypes (51% 6 , 49% B2 The r a t e of I V drug delivery is affected by many factors including c h a r a c t e r i s t i c s of the drug, I V flow r a t e , and s i t e of injection i n t o the system. Because of the frequent use of CS i n pedi a t r i c patients, we examined the r a t e of CS delivery from a standard pediatric I V infusion s e t (~u r e t r o l~~r a v e n o l )
. Using 3 flow r a t e s , and 3 i n j e c t i o n s i t e s (buretrol, y s i t e , f l a s h b a l l ) , timed samples of the I V f l u i d delivered from the s e t were collected f o r 6 h r and analyzed f o r CS by an HPLC method. We found l a r g e differences i n t h e delivery time (min) f o r 95% of the injected CS: S i t e flow r a t e (ml/hr): 29 . . buretrol 150 280 >360 To assess the c l i n i c a l significance of these differences, CS and C steady s t a t e serum concentrations (6 samples over 6 h r ; measured by HPLC) were studied i n f i f t e e n patients (age 0.2-15 yr) receiving CS, 25 mglkg, injected i n t o the buretrol and f l a s h b a l l on consecutive days. Flashball injections resulted i n higher peak CS conc (FO.OO1)-and peak C conc (~0 . 0 0 5 ) i n a shorter time from the s t a r t of infusion (~0 . 0 0 5 ) . A t flow r a t e s > 7 mllhr, trough conc and area under the curve were similar with the two s i t e s . These data show the importance of defining I V flow r a t e s and drug i n j e c t i o n s i t e s when monitoring s i n g l e serum CS or C conc or when calculating k i n e t i c parameters.
KINETICS OF CHLORAMPHENICOL (C) AND ITS SUCCINATE
350 ESTER (CS) I N PEDIATRIC PATIENTS. Milap C. Nahata, Dwight A. Powell, John P. Glazer, and Milo D. Hilty, The Ohio S t a t e Univ Colleges of Med and Pharm, and Children's Hosp, Dept of Peds, Columbus, Ohio CS must be hydrolyzed t o C t o provide antimicrobial a c t i v i t y . A thorough knowledge of CS disposition i s needed t o understand C kinetics i n children. Thirty patients (age 1.5 wk-17 yr) were studied t o characterize CS and C kinetics. CS, 25 mg/kg was administered every 6 hr intravenously over 0.5 h r . A t steady s t a t e , blood samples were obtained a t 0, 0.5, 1, 2 , 4 and 6 hr a f t e r s t a r t i n g t h e infusion. I n 10 patients, a l l urine was collected over t h e same 6 hr. CS and C concentrations (conc) were measured by an HPLC method. Peak serum CS conc ranged from 7.38-79.5 mcg/ m l and peak C conc from 9.3-66.21 mcglml. A rapid decline i n serum CS conc was followed by a slow elimination phase i n half of the patients. CS was s t i l l detectable i n serum a t 4 h r i n 10 p a t i e n t s and 6 h r i n 9 patients. Disposition of both CS and C appeared t o be a f i r s t order process. Half-life of CS ranged from 0.3-5.5 h r and of C from 1.6-7.9 hr. Total body clearance of CS ranged from 0.152-3.27 L/kg/hr and of C from 0.043-0.425 L/kg/hr. 5-25% of the t o t a l dose of CS was excreted i n the urine a s e i t h e r C (2-7%) o r CS (3-18%). These data suggest t h a t CS k i n e t i c s may be charac-. terized by a two compartment open model. I t s hydrolysis i s not instantaneous but more variable than previously appreciated. These factors may account f o r the large v a r i a b i l i t y i n C k i n e t i c s found i n our study and described i n previous reports of C pharmacokinetics i n children.
FUROSEMIDE PHARMACOKINETICS AND DRUG RENAL EXCRETION
351 I N PREMATURE INFANTS ON CHRONIC THERAPY Zeba Najak, Eva Harris, Anthony Lazzara, Albert P r u i t t , Emory University School of Medicine, Dept. of Pediatrics, Atlanta, Ga.
During the treatment of 12 normally hydrated prematures with furosemide (F) f o r chronic lung disease (BPD) F serum l e v e l s and urine excretion were measured using gas chromatography. Six hours post drug administration the d i u r e t i c responsewas monitored i n treated group (TG) and compared t o the control group (CG) of 10 premature infants. The mean gestational age of TG was 29 weeks (range 26-31) and of CG was 30 weeks (range 27-36). The TG receiv -ed a ' s i n g l e bolus I V dose of F (lmgm/kg/day) d a i l y f o r 4 t o 7 days. Eight patients entered the study on day 7, and 4 p a t i e n t s were 9-11 days old on entry. Duration of the study was 4-7 days. The mean renal clearance of F on day l(D1) of the study was 0.04 cc/min (range 0.003cc/min t o 0.13cc/min). The mean renal clearance a f t e r 4(D4) or 7(D7) days of therapy was 0.05cc/min (range 0.003cc/min t o 0.12cclmin). On D l mean serum F l e v e l s were 4.6 ugmlml a t 2 hours and 3.66 ugrnlml a t 6 hours a f t e r F. On D4and07 the mean serum l e v e l s were 10.33 ugm/ml (2 hrs) and 6.67 ugm/ml (6 h r s ) . This i s a s i g n i f i c a n t increase i n mean serum l e v e l s (P< .01) from f i r s t day of treatment. 6 hour plasma half l i f e (Tk) i n these patients changed from mean of 5.2 hours (Dl) t o 10 hours (D4 or D7). In 2 p a t i e n t s mean T% over 12 t o 24 hours was 7.15 hours (Dl) and increased t o 26.15 hours. Mean urine volumeduring 6 hours i n TG was 33.9+21 m l and i n CG was 25.3+13 m l (p=.35NS). Six hour sodium excretion was 1 76 m E (TG) a n d 1 45 mEq (CG). ( HMI.E. femt~mles.mg-~ IAnhrane protein, n = 4 a t each age
There was no change in Kg (affinity) with age for either 1 igand. ble conclude that the rmnber of myocardial alAR increases rapidly after birth in rat myocardium and that the pattern i s distinct from that of BAR. W e speculate that the postnatal development of a AR and BAR i s independently regulated in rat myocardium and that a AR are likely t o be linked with postnatal neurosynaptic development d i l e BAR are not.
